Business - Briefly   

USFDA nod for Wockhardt's Ranitidine OTC version

MUMBAI: Wockhardt has received the U.S. Food and Drug Administration (USFDA) approval for marketing Ranitidine 75 mg tablets as an over-the-counter (OTC) product in the U.S. market. Wockhardt's U.S. subsidiary, Wockhardt USA Inc., is expected to launch the anti-ulcer drug shortly, says a release. Ranitidine is the generic version of Pfizer's Zantac 75 mg tablets.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Chidambaram pitches for larger U.S. FDI inflows
Poor infrastructure a major hurdle: U.S. CEOs
10 CBM blocks showcased
Growth opportunity ahead for tooling industry
Market snaps four-day rally
CIL may have to rework strategy
Product patent for Roche
ONGC may sell stake in GAIL
Tata Steel's record salable steel output
Rupee recovers
Canara Bank hikes interest on NRE, FCNR deposits
Bajaj Allianz ties up with UAE Exchange
Joy Alukkas group bags award
Budget a non-event, says Yashwant Sinha
16 Nutrimix units provided bank linkage
Exchange Rates
Bullion Rates
Extension for FDI compliance in telecom
TDSAT asks BSNL to repay Rs. 5 cr. to Idea
Groups to study recommendations
AES Corp. to invest $1.2 b in power plant
GE-Advanced Materials launches ADC
Generali Insurance to partner NIIT Technologies
Macmet India unveils Satelit-3
USFDA nod for Wockhardt's Ranitidine OTC version
Reliance Power Fund invests in Su-Kam
New CEO of Ascendas India

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu